ArticleCancer discovery2017
Loss of MutL Disrupts CHK2-Dependent Cell-Cycle Control through CDK4/6 to Promote Intrinsic Endocrine Therapy Resistance in Primary Breast Cancer.
Registry-linked trialOpen access · greenAbstract read
In one paragraph
Article in Cancer discovery, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07729046 (Neu Direction), which is not on this map. Cited by 50 papers, 1 of them a synthesis that pooled it.
0numbers the graph read from it
0cells of the map it votes in
50citing papers in PubMed, 1 pooled it
5.9field-weighted citation impact, top 3% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
NCT07729046 phase2not yet recruitingnot on this mapstarted 2027, after this paper: background citation
Neu Direction: A Single Center Phase II Randomized Clinical Trial to Assess the Efficacy of Adding HER Inhibition to Standard of Care in Patients With Metastatic MLH1-low Endocrine-resistant ER+/HER2- Breast Cancer
Who cites it
50 citing papers in PubMed, 1 synthesis or guideline pooled it, 80 citations in OpenAlex.
- Systematic Review of Molecular Biomarkers Predictive of Resistance to CDK4/6 Inhibition in Metastatic Breast Cancer.JCO precision oncology · 2022Pooled it
- Multidimensional molecular mechanisms of drug resistance in breast cancer: Implications for clinical decision‑making and treatment strategies (Review).Oncology reports · 2026Review
- Cancer-associated adipocytes confer CDK4/6 inhibitor resistance in ER+ breast cancer through an IL-6/STAT3/SREBF2 axis coupled with cholesterol metabolism and cell cycle reprogramming.International journal of biological sciences · 2026Article
- Aberrant cytoplasmic localization of MLH1 characterizes a cell population that seeds breast cancer recurrence.Nature communications · 2025Article
- CDK4/6 Inhibitors in Breast Cancer-Who Should Receive Them?International journal of molecular sciences · 2025Review
- Circulating Tumor DNA Genotyping of Intrinsic and Acquired Gene Alterations in Patients With Advanced Breast Cancer Receiving Palbociclib: Biomarker Results From POLARIS Study.JCO precision oncology · 2025Article
- Advances in diagnostic and therapeutic applications of mismatch repair loss in cancer.DNA repair · 2025Review
- Multimodal integration using a machine learning approach facilitates risk stratification in HR+/HER2- breast cancer.Cell reports. Medicine · 2025Article
- CD4Science advances · 2025Article
- Nonrepair functions of DNA mismatch repair proteins: new avenues for precision oncology.Trends in cancer · 2025Review
- Genetic prediction of the casual relationship between micronutrients and ER+ breast cancer: a Mendelian randomized study.Frontiers in genetics · 2025Article
- Article
- Kinome Reprogramming Is a Targetable Vulnerability in ESR1 Fusion-Driven Breast Cancer.Cancer research · 2023Article
- Low and Ultra-Low HER2 in Human Breast Cancer: An Effort to Define New Neoplastic Subtypes.International journal of molecular sciences · 2023Review
- Molecular portraits of cell cycle checkpoint kinases in cancer evolution, progression, and treatment responsiveness.Science advances · 2023Article
- HER2-Low Breast Cancer: Current Landscape and Future Prospects.Breast cancer (Dove Medical Press) · 2023Review
- Nrf2 overexpression increases the resistance of acute myeloid leukemia to cytarabine by inhibiting replication factor C4.Cancer gene therapy · 2022Article
- Comprehensive Transcriptomic and Proteomic Analyses Identify a Candidate Gene Set in Cross-Resistance for Endocrine Therapy in Breast Cancer.International journal of molecular sciences · 2022Article
- Functions of Breast Cancer Predisposition Genes: Implications for Clinical Management.International journal of molecular sciences · 2022Review
- Association between germline pathogenic variants and breast cancer risk in Japanese women: The HERPACC study.Cancer science · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
19 authors at 1 institution in 1 country.
Svasti HaricharanLester and Sue Smith Breast Center, Baylor College of Medicine, Houston, Texas.
Nindo PunturiLester and Sue Smith Breast Center, Baylor College of Medicine, Houston, Texas.
Purba SinghLester and Sue Smith Breast Center, Baylor College of Medicine, Houston, Texas.
Kimberly R HollowayLester and Sue Smith Breast Center, Baylor College of Medicine, Houston, Texas.
Meenakshi AnuragLester and Sue Smith Breast Center, Baylor College of Medicine, Houston, Texas.
Jacob SchmelzLester and Sue Smith Breast Center, Baylor College of Medicine, Houston, Texas.
Cheryl SchmidtLester and Sue Smith Breast Center, Baylor College of Medicine, Houston, Texas.
Jonathan T LeiLester and Sue Smith Breast Center, Baylor College of Medicine, Houston, Texas.
Vera SumanAlliance Statistics and Data Center, Mayo Clinic, Rochester, Minnesota.
Kelly HuntDepartment of Breast Surgery, The University of Texas MD Anderson Cancer Center, Houston, Texas.
John A OlsonDepartment of Surgery, University of Maryland School of Medicine, Baltimore, Maryland.
Jeremy HoogDivision of Oncology, Department of Internal Medicine, Washington University School of Medicine, Saint Louis, Missouri.
Shunqiang LiDivision of Oncology, Department of Internal Medicine, Washington University School of Medicine, Saint Louis, Missouri.
Shixia HuangDan L. Duncan Cancer Center, Baylor College of Medicine, Houston, Texas.
Dean P EdwardsDan L. Duncan Cancer Center, Baylor College of Medicine, Houston, Texas.
Shyam M KavuriLester and Sue Smith Breast Center, Baylor College of Medicine, Houston, Texas.
Matthew N BainbridgeDepartment of Molecular and Human Genetics, Baylor College of Medicine, Houston, Texas.
Cynthia X MaDivision of Oncology, Department of Internal Medicine, Washington University School of Medicine, Saint Louis, Missouri.
Matthew J EllisLester and Sue Smith Breast Center, Baylor College of Medicine, Houston, Texas. mjellis@bcm.edu.
Baylor College of Medicine · US
Funding
Member Site CoreU10CA180821 · NCI · BRIGHAM AND WOMEN'S HOSPITAL · PI Evanthia Galanis · 2014 to 2026
$177.3MWashington University Center for Cellular ImagingP30CA091842 · NCI · WASHINGTON UNIVERSITY · PI TIMOTHY J. EBERLEIN · 2001 to 2026
$128.0MStatistics CoreU10CA180882 · NCI · MAYO CLINIC ROCHESTER · PI Sumithra Jay Mandrekar · 2014 to 2026
$115.0MTumor BiologyP30CA125123 · NCI · BAYLOR COLLEGE OF MEDICINE · PI DAVID R ROWLEY · 2007 to 2026
$73.9MTHE ALLIANCE NCTN BIOREPOSITORY AND BIOSPECIMEN RESOURCEU24CA196171 · NCI · WASHINGTON UNIVERSITY · PI Mine Cicek, Wendy Frankel · 2015 to 2026
$35.0MWashington University/ Siteman Cancer Center Lead Academic SiteU10CA180833 · NCI · WASHINGTON UNIVERSITY · PI BARTLETT, NANCY L, KOZOWER, BENJAMIN D · 2014 to 2018
$7.6MUT MD Anderson Cancer Center Network Lead Academic Participating Site (LAP)U10CA180858 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI HUNT, KELLY K, PINNIX, CHELSEA CAMILLE · 2014 to 2018
$5.6MNOVEL BIOMARKERS FOR AROMATASE INHIBITOR THERAPYR01CA095614 · NCI · WASHINGTON UNIVERSITY · PI ELLIS, MATTHEW J, LUO, JINGQIN · 2003 to 2013
$5.6MWUSM CANCER AND LEUKEMIA GROUP BU10CA077440 · NCI · WASHINGTON UNIVERSITY · PI BARTLETT, NANCY L · 1998 to 2013
$4.4MTraining Program in Translational Biology and Molecular MedicineT32GM088129 · NIGMS · BAYLOR COLLEGE OF MEDICINE · PI ROONEY, CLIONA M., VAN DEN VEYVER, IGNATIA B · 2010 to 2019
$3.0MNCI NIH HHS P30 CA091842NCI NIH HHS P30 CA125123NCI NIH HHS R01 CA095614NCI NIH HHS U10 CA077440NCI NIH HHS U10 CA180821NCI NIH HHS U10 CA180833NCI NIH HHS U10 CA180858NCI NIH HHS U10 CA180882NCI NIH HHS U24 CA196171NIGMS NIH HHS T32 GM088129
Abstract
Significant endocrine therapy-resistant tumor proliferation is present in ≥20% of estrogen receptor-positive (ER
Indexed as
Drug Resistance, NeoplasmAnimalsAromatase InhibitorsBreast NeoplasmsCell CycleCell Line, TumorCheckpoint Kinase 2Cyclin-Dependent Kinase 4Cyclin-Dependent Kinase 6FemaleHumansMCF-7 CellsMiceMutL ProteinsNeoplasm TransplantationReceptors, EstrogenAromatase InhibitorsCDK4 protein, humanCDK6 protein, humanCheckpoint Kinase 2CHEK2 protein, humanCyclin-Dependent Kinase 4Cyclin-Dependent Kinase 6MutL ProteinsReceptors, Estrogen
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
NCT07729046ClinicalTrials.gov
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.